Cargando…
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
PURPOSE: The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) following bodyweight-based dosing. METHODS: Model si...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708381/ https://www.ncbi.nlm.nih.gov/pubmed/33258982 http://dx.doi.org/10.1007/s11095-020-02933-6 |
_version_ | 1783617544707375104 |
---|---|
author | Lu, Dan Lu, Tong Shi, Rong Gibiansky, Leonid Agarwal, Priya Shemesh, Colby S. Dere, Randall C. Ogbu, Uzor Hirata, Jamie Chanu, Pascal Girish, Sandhya Jin, Jin Yan Li, Chunze Miles, Dale |
author_facet | Lu, Dan Lu, Tong Shi, Rong Gibiansky, Leonid Agarwal, Priya Shemesh, Colby S. Dere, Randall C. Ogbu, Uzor Hirata, Jamie Chanu, Pascal Girish, Sandhya Jin, Jin Yan Li, Chunze Miles, Dale |
author_sort | Lu, Dan |
collection | PubMed |
description | PURPOSE: The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) following bodyweight-based dosing. METHODS: Model simulations based on individual empirical Bayes estimates were used to evaluate the impact of intrinsic/extrinsic factors as patient subgroups on Cycle 6 exposures. Intrinsic factors included bodyweight, age, sex, hepatic and renal functions. Extrinsic factors included rituximab/obinutuzumab or bendamustine combination with pola and manufacturing process. The predicted impact on exposures along with the established exposure-response relationships were used to assess clinical relevance. RESULTS: No clinically meaningful differences in Cycle 6 pola exposures were found for the following subgroups: bodyweight 100–146 kg versus 38–<100 kg, age ≥ 65 years versus <65 years, female versus male, mild hepatic impairment versus normal, mild-to-moderate renal impairment versus normal. Co-administration of rituximab/obinutuzumab or bendamustine, and change in the pola manufacturing process, also had no meaningful impact on PK. CONCLUSIONS: In patients with NHL, bodyweight-based dosing is adequate, and no further dose adjustment is recommended for the heavier subgroup (100–146 kg). In addition, no dose adjustments are recommended for other subgroups based on intrinsic/extrinsic factors evaluated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-020-02933-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7708381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-77083812020-12-03 Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma Lu, Dan Lu, Tong Shi, Rong Gibiansky, Leonid Agarwal, Priya Shemesh, Colby S. Dere, Randall C. Ogbu, Uzor Hirata, Jamie Chanu, Pascal Girish, Sandhya Jin, Jin Yan Li, Chunze Miles, Dale Pharm Res Research Paper PURPOSE: The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) following bodyweight-based dosing. METHODS: Model simulations based on individual empirical Bayes estimates were used to evaluate the impact of intrinsic/extrinsic factors as patient subgroups on Cycle 6 exposures. Intrinsic factors included bodyweight, age, sex, hepatic and renal functions. Extrinsic factors included rituximab/obinutuzumab or bendamustine combination with pola and manufacturing process. The predicted impact on exposures along with the established exposure-response relationships were used to assess clinical relevance. RESULTS: No clinically meaningful differences in Cycle 6 pola exposures were found for the following subgroups: bodyweight 100–146 kg versus 38–<100 kg, age ≥ 65 years versus <65 years, female versus male, mild hepatic impairment versus normal, mild-to-moderate renal impairment versus normal. Co-administration of rituximab/obinutuzumab or bendamustine, and change in the pola manufacturing process, also had no meaningful impact on PK. CONCLUSIONS: In patients with NHL, bodyweight-based dosing is adequate, and no further dose adjustment is recommended for the heavier subgroup (100–146 kg). In addition, no dose adjustments are recommended for other subgroups based on intrinsic/extrinsic factors evaluated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-020-02933-6) contains supplementary material, which is available to authorized users. Springer US 2020-12-01 2020 /pmc/articles/PMC7708381/ /pubmed/33258982 http://dx.doi.org/10.1007/s11095-020-02933-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Paper Lu, Dan Lu, Tong Shi, Rong Gibiansky, Leonid Agarwal, Priya Shemesh, Colby S. Dere, Randall C. Ogbu, Uzor Hirata, Jamie Chanu, Pascal Girish, Sandhya Jin, Jin Yan Li, Chunze Miles, Dale Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma |
title | Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma |
title_full | Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma |
title_fullStr | Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma |
title_full_unstemmed | Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma |
title_short | Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma |
title_sort | application of a two-analyte integrated population pharmacokinetic model to evaluate the impact of intrinsic and extrinsic factors on the pharmacokinetics of polatuzumab vedotin in patients with non-hodgkin lymphoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708381/ https://www.ncbi.nlm.nih.gov/pubmed/33258982 http://dx.doi.org/10.1007/s11095-020-02933-6 |
work_keys_str_mv | AT ludan applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT lutong applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT shirong applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT gibianskyleonid applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT agarwalpriya applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT shemeshcolbys applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT dererandallc applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT ogbuuzor applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT hiratajamie applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT chanupascal applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT girishsandhya applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT jinjinyan applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT lichunze applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma AT milesdale applicationofatwoanalyteintegratedpopulationpharmacokineticmodeltoevaluatetheimpactofintrinsicandextrinsicfactorsonthepharmacokineticsofpolatuzumabvedotininpatientswithnonhodgkinlymphoma |